Yourgene Health launches first oncology product

Writer, Stock Market Wire
Wednesday, September 18, 2019 - 07:36

Molecular diagnostics group Yourgene Health said it had launched its first oncology product.

The Elucigene DPYD assay was a chemotoxicity diagnostic assay that could identify cancer patients with Dihydropyrimidine Dehydrogenase deficiency.

The condition can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil, commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers.


Related content

Yourgene Health to exhibit at Houston conference

Molecular diagnostics group Yourgene Health said it would be exhibiting at a key conference in Houston.

The company said it would exhibit at the American...

Tue, 15/10/2019 - 09:14


Yourgene Health revenue almost doubles in first half as expected

Molecular diagnostics group Yourgene Health said its revenue in the first half almost doubled, in line with its expectations.

Revenue for the six months through...

Mon, 14/10/2019 - 07:34


Yourgene Health posts first profit since 2014 market listing

Molecular diagnostics group Yourgene Health swung to a full-year profit, as it grew revenue and cut expenses.

Pre-tax profit for the year through March amounted...

Wed, 10/07/2019 - 08:30


Yourgene Health beats expectations with 45% revenue improvement

Molecular diagnostics group Yourgene Health said its annual rose 45%, beating market expectations.

Revenue for the year through March jumped to £8.9m, with growth occurring...

Mon, 08/04/2019 - 07:41


Yourgene Health restructures financing arrangement with Life Technologies

Molecular diagnostics group Yourgene Health said it had restructured its financial and commercial relationship with Life Technologies.

Life Technologies had exercised warrants at 9.2p per...

Mon, 18/02/2019 - 09:48